Stock Research for ALIOF

ALIOF

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ALIOF Stock Chart & Research Data

The ALIOF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALIOF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ALIOF Due diligence Resources & Stock Charts

The ALIOF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ALIOF Detailed Price Forecast - CNN Money CNN View ALIOF Detailed Summary - Google Finance
Yahoo View ALIOF Detailed Summary - Yahoo! Finance Zacks View ALIOF Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ALIOF Trends & Analysis - Trade-Ideas Barrons View ALIOF Major Holders - Barrons
NASDAQ View ALIOF Call Transcripts - NASDAQ Seeking View ALIOF Breaking News & Analysis - Seeking Alpha
Spotlight View ALIOF Annual Report - CompanySpotlight.com OTC Report View ALIOF OTC Short Report - OTCShortReport.com
TradeKing View ALIOF Fundamentals - TradeKing Charts View ALIOF SEC Filings - Bar Chart
WSJ View Historical Prices for ALIOF - The WSJ Morningstar View Performance/Total Return for ALIOF - Morningstar
MarketWatch View the Analyst Estimates for ALIOF - MarketWatch CNBC View the Earnings History for ALIOF - CNBC
StockMarketWatch View the ALIOF Earnings - StockMarketWatch MacroAxis View ALIOF Buy or Sell Recommendations - MacroAxis
Bullish View the ALIOF Bullish Patterns - American Bulls Short Pains View ALIOF Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ALIOF Stock Mentions - StockTwits PennyStocks View ALIOF Stock Mentions - PennyStockTweets
Twitter View ALIOF Stock Mentions - Twitter Invest Hub View ALIOF Investment Forum News - Investor Hub
Yahoo View ALIOF Stock Mentions - Yahoo! Message Board Seeking Alpha View ALIOF Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for ALIOF - SECform4.com Insider Cow View Insider Transactions for ALIOF - Insider Cow
CNBC View ALIOF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ALIOF - OTC Markets
Yahoo View Insider Transactions for ALIOF - Yahoo! Finance NASDAQ View Institutional Holdings for ALIOF - NASDAQ


Stock Charts

FinViz View ALIOF Stock Insight & Charts - FinViz.com StockCharts View ALIOF Investment Charts - StockCharts.com
BarChart View ALIOF Stock Overview & Charts - BarChart Trading View View ALIOF User Generated Charts - Trading View


Latest Financial News for ALIOF

Why 2017 Was a Year to Remember for Johnson & Johnson
Posted on Tuesday December 19, 2017

Three keys behind the healthcare giant's tremendous year in 2017 that could be critical for next year also.


Idorsia to get $230 million from J&J in latest hypertension deal
Posted on Sunday December 03, 2017

Idorsia (IDIA.S), the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J) (JNJ.N), will receive a one-time payment of $230 million (171 million pounds)from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension. Aprocitentan is a metabolite of Actelion's Opsumit. Idorsia and J&J are seeking to develop it to treat hypertension patients whose disease has failed at least three therapies.


Idorsia to get $230 mln from J&J in latest hypertension deal
Posted on Sunday December 03, 2017

Idorsia, the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J), will receive a one-time payment of $230 million from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension. Aprocitentan is a metabolite of Actelion's Opsumit. Idorsia and J&J are seeking to develop it to treat hypertension patients whose disease has failed at least three therapies.


Genmab and J&J 'love' partnership as some ponder takeover
Posted on Thursday November 30, 2017

Genmab was Europe's second biggest biotech company, until its partner Johnson & Johnson bought Switzerland's Actelion for $30 billion (£22.30 billion) this year and propelled the Danish antibody specialist to the top spot. Now some investors wonder if the same fate might await Genmab, worth $12 billion, given the soaraway success of its blood cancer drug Darzalex. J&J sells the drug and pays Genmab a royalty of 12 to 20 percent.


Enter a stock symbol to view the stock details.